Concentration and Methylation of Cell-Free DNA from Blood Plasma as Diagnostic Markers of Renal Cancer

Table 4

Diagnostic data analysis for the discrimination of renal cancer patients and healthy subjects using cfDNA methylation of various genes alone and in combination.

Markers	Renal cell carcinoma ()	Healthy controls ()	, value	Sensitivity, %	Specificity, %
LRRC3B	20 (74.1%)	5 (33.3%)	0.01	74.1	66.7
RASSF1	17 (63.0 %)	1 (6.7%)	0.0058	62.9	93.3
FHIT	15 (55.6%)	0 (0%)	0.0003	55.6	100
APC	14 (51.9%)	1 (6.7%)	0.0034	51.9	93.3
VHL	0 (0%)	0 (0%)		0	100
ITGA9	0 (0%)	0 (0%)		0	100
RASSF1 or FHIT or APC	25 (92.3%)	2 (13.3%)	<0.0001	92.3	86.7
RASSF1 or FHIT	21 (77.8%)	1 (6.7%)	<0.0001	77.8	93.3
RASSF1 or APC	21 (77.8%)	1 (6.7%)	<0.0001	77.8	93.3

Sensitivity was calculated as a percentage of positive results from a number of tested RCC patients; specificity was calculated as a percentage of negative tests from a given number of healthy donors.